Abstract
Bevacizumab is a recombinant, humanized antivascular endothelial growth factor (VEGF) monoclonal antibody that neutralizes the biological activity of VEGF and inhibits tumour angiogenesis.
In two pivotal, well designed, phase III, clinical trials (GOG-0218 and ICON7) in women with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer, first-line treatment with bevacizumab in combination with standard chemotherapy (carboplatin plus paclitaxel) followed by maintenance treatment with bevacizumab alone significantly prolonged progression-free survival relative to standard chemotherapy.
A subgroup analysis of ICON7 suggested that bevacizumab therapy may also be beneficial in patients at high risk of disease progression.
In GOG-0218, health-related quality of life (HR-QOL) deteriorated temporarily (during the chemotherapy phase) and slightly, although statistically significantly, with bevacizumab in combination with standard chemotherapy followed by bevacizumab maintenance relative to standard chemotherapy plus placebo maintenance. In ICON7, HR-QOL did not differ to a clinically significant extent between patients receiving bevacizumab plus standard chemotherapy followed by bevacizumab maintenance and those receiving standard chemotherapy alone.
Bevacizumab combination therapy had generally acceptable tolerability in these studies, with the nature of adverse events generally similar to that observed in previous clinical trials in patients with other solid tumours.
Similar content being viewed by others
References
Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011 Mar 30; 61 (2): 69–90
Colombo N, Peiretti M, Parma G, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010 May; 21 Suppl. 5: v23-30
Vaughan S, Coward JI, Bast RCJ, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 2011 Oct; 11 (10): 719–25
Burger RA. Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol 2007; 25 (20): 2902–8
Ledermann JA, Marth C, Carey MS, et al. Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer. Int J Gynecol Cancer 2011; 21 (4): 763–70
Teoh DG, Secord AA. Antiangiogenic therapies in epithelial ovarian cancer. Cancer Control 2011 Jan; 18 (1): 31–43
Kerbel RS. Tumor angiogenesis. N Engl J Med 2008 May 8; 358 (19): 2039–49
Kraft A, Weindel K, Ochs A, et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 1999 Jan 1; 85 (1): 178–87
Brustmann H. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with topoisomerase II alpha and prognosis. Gynecol Oncol 2004 Oct; 95 (1): 16–22
Manenti L, Paganoni P, Floriani I, et al. Expression levels of vascular endothelial growth factor, matrix metalloprotei-nases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. Eur J Cancer 2003 Sep; 39 (13): 1948–56
Wong C, Wellman TL, Lounsbury KM. VEGF and HIF-1alpha expression are increased in advanced stages of epithelial ovarian cancer. Gynecol Oncol 2003 Dec; 91 (3): 513–7
European Medicines Agency. Avastin (bevacizumab): summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000582/WC500029271.pdf [Accessed 2012 Jan 12]
European Medicines Agency. Avastin (bevacizumab): summary of opinion, post authorisation (EMA/CHMP/569545/2011) [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/000582/WC500112811.pdf [Accessed 2011 Nov 18]
Lyseng-Williamson KA, Robinson DM. Bevacizumab: a review of its use in advanced colorectal cancer, breast cancer, and NSCLC. Am J Cancer 2006; 5 (1): 43–60
Scott LJ. Bevacizumab: in first-line treatment of metastatic breast cancer. Drugs 2007; 67 (12): 1793–9
Croom KF, Dhillon S. Bevacizumab: a review of its use in combination with paclitaxel or capecitabine as first-line therapy for HER2-negative metastatic breast cancer. Drugs 2011 Nov 12; 71 (16): 2213–29
Gerber HP, Ferrara N. Pharmacology and pharmaco-dynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005 Feb 1; 65 (3): 671–80
Wang Y, Fei D, Vanderlaan M, et al. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 2004; 7 (4): 335–45
Mabuchi S, Terai Y, Morishige K, et al. Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model. Clin Cancer Res 2008; 14 (23): 7781–9
Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006 Feb 10; 24 (5): 769–77
Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19 (3): 843–50
Margolin K, Gordon MS, Holmgren E, et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 2001; 19 (3): 851–6
Hsei V, Deguzman GG, Nixon A, et al. Complexation of VEGF with bevaczumab decreases VEGF clearance in rats. Pharm Res 2002; 19 (11): 1753–6
Mabuchi S, Kawase C, Altomare DA, et al. Vascular endo-thelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary. Mol Cancer Ther 2010 Aug; 9 (8): 2411–22
Presta LG, Chen H, O’Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57 (20): 4593–9
Yanagisawa M, Yorozu K, Kurasawa M, et al. Bevacizumab improves the delivery and efficacy of paclitaxel. Anticancer Drugs 2010; 21 (7): 687–94
Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362 (6423): 841–4
Hu L, Hofmann J, Zaloudek C, et al. Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 2002 Nov; 161 (5): 1917–24
Belotti D, Calcagno C, Garofalo A, et al. Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion. Mol Cancer Res 2008 Apr; 6 (4): 525–34
Smerdel MP, Steffensen KD, Waldstrom M, et al. The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab. Gynecol Oncol 2010; 118 (2): 167–71
Han ES, Burger RA, Darcy KM, et al. Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer. Gynecol Oncol 2010; 119 (3): 484–90
Randall LM, Monk BJ. Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol 2010; 117 (3): 497–504
Stone RL, Sood AK, Coleman RL. Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer. Lancet Oncol 2010 May; 11 (5): 465–75
Gressett SM, Shah SR. Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother 2009 Mar; 43 (3): 490–501
Wu JY, Wu XN, Ding L, et al. Phase I safety and pharma-cokinetic study of bevacizumab in Chinese patients with advanced cancer. Chin Med J 2010; 123 (7): 901–6
European Medicines Agency. Avastin: European public assessment report: scientific discussion [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000582/WC500029262.pdf [Accessed 2011 Nov 29]
Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011 Dec 29; 365 (26): 2473–83
Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011 Dec 29; 365 (26): 2484–96
Micha JP, Goldstein BH, Rettenmaier MA, et al. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int J Gynecol Cancer 2007; 17 (4): 771–6
Penson RT, Dizon DS, Cannistra SA, et al. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced Mullerian tumors. J Clin Oncol 2010; 28 (1): 154–9
Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA, et al. Reliability and validity of the functional assessment of cancer therapy-ovarian. J Clin Oncol 2001 Mar 15; 19 (6): 1809–17
Greimel E, Bottomley A, Cull A, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. Eur J Cancer 2003 Jul; 39 (10): 1402–8
Burger R, Brady M, Bookman M, et al. Prospective investigation of risk factors for gastrointestinal adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer: a Gynecologic Oncology Group study [abstract no. 7]. Gynecol Oncol 2011; 120 Suppl. 1: S5
Cohn DE, Kim KH, Resnick KE, et al. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol 2011; 29 (10): 1247–51
Neumann PJ, Sandberg EA, Bell CM, et al. Are pharmaceuticals cost-effective? A review of the evidence. Health Aff (Millwood) 2000; 19 (2): 92–109
Nadler E, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value?. Oncologist 2006; 11 (2): 90–5
Thigpen T, duBois A, McAlpine J, et al. First-line therapy in ovarian cancer trials. Int J Gynecol Cancer 2011; 21 (4): 756–62
Aghajanian C, Finkler NJ, Rutherford T, et al. OCEANS: a randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC) [abstract]. J Clin Oncol 2011; 29 (15 Suppl.)
Acknowledgements and Disclosures
The manuscript was reviewed by: A. Maneo, Unit of Gynecologic Oncology, Azienda Ospedaliera Bolognini, Seriate, Italy; M. Markman, Cancer Treatment Centers of America, Eastern Regional Medical Center, Philadelphia, PA, USA; F. Muggia, NYU Cancer Institute, New York University Langone Medical Center, New York, NY, USA.
The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dhillon, S. Bevacizumab Combination Therapy. Drugs 72, 917–930 (2012). https://doi.org/10.2165/11208940-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11208940-000000000-00000